AgomAb Therapeutics N.V. American Depositary Shares
AgomAb Therapeutics N.V. American Depositary Shares
- Market cap
- $286.62M
Your view on AGMB
Overview
What the company does, where it operates, and who runs it.
About AgomAb Therapeutics N.V. American Depositary Shares
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Tim Knotnerus
- Headquarters
- Posthoflei 1/6, Antwerp, VL, BE
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Tim Knotnerus
- Headquarters
- Posthoflei 1/6, Antwerp, VL, BE
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist.
Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials.
Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF.
This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for AgomAb Therapeutics N.V. American Depositary Shares. Starting points for AgomAb Therapeutics N.V. American Depositary Shares: EPS -$0.73, beta 1.80 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for AgomAb Therapeutics N.V. American Depositary Shares. Trailing twelve-month EPS for AgomAb Therapeutics N.V. American Depositary Shares stands at -$0.73. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Targets, low to high
Earnings per share estimates
| Per share | This quarterMar 2026 | Next quarterJun 2026 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | EUR 1.18 | −EUR 0.96 | −EUR 1.71 | −EUR 2.01 |
| Lowest estimate | EUR 1.04 | −EUR 1.04 | −EUR 2.02 | −EUR 2.62 |
| Highest estimate | EUR 1.29 | −EUR 0.91 | −EUR 1.36 | −EUR 1.33 |
| Number of analysts | 2 | 2 | 6 | 6 |
| A year ago | — | — | −EUR 1.28 | — |
| Growth vs a year ago | — | — | −33.7% | — |
Revenue estimates
| Total | This quarterMar 2026 | Next quarterJun 2026 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | EUR 0.00 | EUR 0.00 | EUR 505517.00 | EUR 606625.00 |
| Lowest estimate | EUR 0.00 | EUR 0.00 | EUR 505517.00 | EUR 606625.00 |
| Highest estimate | EUR 0.00 | EUR 0.00 | EUR 505517.00 | EUR 606625.00 |
| Number of analysts | 0 | 0 | 6 | 6 |
| A year ago | — | — | EUR 0.00 | — |
| Growth vs a year ago | — | — | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for AgomAb Therapeutics N.V. American Depositary Shares. AgomAb Therapeutics N.V. American Depositary Shares has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| ACRSAclaris Therapeutics, Inc. | Healthcare | Biotechnology | $555.1M | ||
| ALMSAlumis Inc. Common Stock | Healthcare | Biotechnology | $568.9M | ||
| ANABAnaptysBio, Inc. | Healthcare | Biotechnology | $1.4B | ||
| EQEquillium, Inc. | Healthcare | Biotechnology | $90.6M | ||
| ODTXOdyssey Therapeutics, Inc. | Healthcare | Biotechnology | $912.3M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PTCHFPureTech Health plc | Healthcare | OTC | $410.4M | ||
| PTCTPTC Therapeutics, Inc. | Healthcare | NASDAQ | $5.0B | ||
| PTGXProtagonist Therapeutics, Inc. | Healthcare | NASDAQ | $8.3B | ||
| PTHSPelthos Therapeutics Inc. | Healthcare | AMEX | $27.9M | ||
| PTIXProtagenic Therapeutics, Inc. | Healthcare | NASDAQ | $470,654 | ||
| PTNPalatin Technologies, Inc. | Healthcare | NASDAQ | $9.2M | ||
| PTX.AXPrescient Therapeutics Limited | Healthcare | ASX | — | ||
| PULMPulmatrix, Inc. | Healthcare | NASDAQ | $4.9M | ||
| PVCTProvectus Biopharmaceuticals, Inc. | Healthcare | OTC | $18.7M | ||
| PVLAPalvella Therapeutics, Inc. | Healthcare | NASDAQ | $2.1B | ||
| PXMDPaxMedica, Inc. Common Stock | Healthcare | OTC | $37,879 | ||
| PXXLFPoxel S.A. | Healthcare | OTC | $13.4M | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| SBIOALPS Medical Breakthroughs ETF | $187M in assets | 0.19% | |
Largest holders first, then the funds most concentrated in AGMB.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold AgomAb Therapeutics N.V. American Depositary Shares, and how their positions are changing. At a $286.6M market value, institutional positions materially move AgomAb Therapeutics N.V. American Depositary Shares's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by AgomAb Therapeutics N.V. American Depositary Shares executives and directors. Shares of AgomAb Therapeutics N.V. American Depositary Shares have traded between $8.75 and $17.82 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for AgomAb Therapeutics N.V. American Depositary Shares. Coverage tracks AgomAb Therapeutics N.V. American Depositary Shares within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of AgomAb Therapeutics N.V. American Depositary Shares.